Compounds > bpdz 44
Page last updated: 2024-10-15

bpdz 44

Description

BPDZ 44: an activator of ATP-sensitive potassium channels; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135410908
CHEMBL ID32111
SCHEMBL ID2341320
MeSH IDM0231028

Synonyms (12)

Synonym
2h-pyrido(4,3-e)-1,2,4-thiadiazin-3-amine, n-(1,2-dimethylpropyl)-, 1,1-dioxide, (+-)-
152382-67-7
3-(1',2'-dimethylpropyl)amino-4h-pyrido(4,3-e)(1,2,4)thiadiazine 1,1-dioxide
bpdz-44
bpdz 44
CHEMBL32111
n-(3-methylbutan-2-yl)-1,1-dioxo-4h-pyrido[4,3-e][1,2,4]thiadiazin-3-amine
SCHEMBL2341320
DTXSID70934489
3-[(3-methylbutan-2-yl)imino]-3,4-dihydro-1lambda~6~-pyrido[4,3-e][1,2,4]thiadiazine-1,1(2h)-dione
cid 132945
n-(3-methylbutan-2-yl)-1,1-dioxo-4h-pyrido[4,3-e][1,2,4]thiadiazin-3-imine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)EC2x (µMol)1,000.00001.60001.60001.6000AID92192
Glutamate receptor 1Rattus norvegicus (Norway rat)EC5X (µMol)1,000.00009.80009.80009.8000AID92196
Glutamate receptor 2Rattus norvegicus (Norway rat)EC2x (µMol)1,000.00001.60001.60001.6000AID92192
Glutamate receptor 2Rattus norvegicus (Norway rat)EC5X (µMol)1,000.00009.80009.80009.8000AID92196
Glutamate receptor 3Rattus norvegicus (Norway rat)EC2x (µMol)1,000.00001.60001.60001.6000AID92192
Glutamate receptor 3Rattus norvegicus (Norway rat)EC5X (µMol)1,000.00009.80009.80009.8000AID92196
Glutamate receptor 4Rattus norvegicus (Norway rat)EC2x (µMol)1,000.00001.60001.60001.6000AID92192
Glutamate receptor 4Rattus norvegicus (Norway rat)EC5X (µMol)1,000.00009.80009.80009.8000AID92196
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID195750Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 10 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID195752Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 50 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID195201In vitro inhibition of 30 mM KCl-induced contraction of rat aorta rings.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID195221Percentage of residual contractile response in isolated rat aorta; +++ indicates that a maximal vasorelaxant activity was observed at 500 uM1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID248105Concentration required for relaxation of the 30 mM KCl-induced contraction of rat aortic rings2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID189326Residual insulin release from rat pancreatic islets incubated in the presence of an insulinotropic (16.7 uM) glucose concentration and at a 50 uM concentration of drug1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID79039In vitro inhibition electrically stimulated guinea pig ileum segment contraction.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID246915Concentration giving 50% relaxation of the 30 mM KCl-induced contraction of rat aortic rings (n=8)2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID189324Effect on Insulin secretion from rat pancreatic islets (RIS) in the presence of 16.7 mM glucose at 10 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID92196concentration of drug giving a 5-fold increase of the magnitude of the current induced by Ionotropic glutamate receptor AMPA (30 uM) and measured in Xenopus Oocytes expressing Rat Cortex AMPA Receptors1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID195748Percentage residual insulin release by the compound at 1 uM from rat pancreatic islets1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID195187Effective dose to give 50% relaxation of the KCl induced contraction1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID92192Concentration of drug giving a 2-fold increase of the magnitude of the current induced by Ionotropic glutamate receptor AMPA (30 uM) and measured in Xenopus Oocytes expressing Rat Cortex AMPA Receptors1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID195734Percentage residual insulin secretion at 10 uM dose from pancreatic islets incubated in the presence of 16.7 mM glucose2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID253212Effect on insulin secretion from rat pancreatic islets at 50 uM concentration (n=23)2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID253186Effect on insulin secretion from rat pancreatic islets at 1 uM concentration (n=19)2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID76811Inhibition of electrically stimulated contractions of guinea pig ileum segments.2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID195745Residual insulin release from rat pancreatic islets at a concentration of 50 uM1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID195751Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 100 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID195749Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 1 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID195735In vitro percentage residual insulin secretion at 50 uM dose from rat pancreatic islets incubated in the presence of 16.7 mM glucose.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID195753Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 500 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID195747Percentage residual insulin release by the compound at 10 uM from rat pancreatic islets1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID176359Concentration giving 50% relaxation of the 30 mM KCL-induced contraction of rat aorta rings2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID195733Percentage residual insulin secretion at 1 uM dose from pancreatic islets incubated in the presence of 16.7 mM glucose2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID249397ED50/IC50 ratio was determined2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID189325Insulin secretion from rat pancreatic islets (RIS) in the presence of 16.7 mM glucose at 50 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID253199Effect on insulin secretion from rat pancreatic islets at 10 uM concentration (n=23)2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (78.57)18.2507
2000's3 (21.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glyceraldehyde
Glyceraldehyde: An aldotriose containing the propionaldehyde structure with hydroxy groups at the 2- and 3-positions. It is involved in the formation of ADVANCED GLYCOSYLATION END PRODUCTS.. glyceraldehyde : An aldotriose comprising propanal having hydroxy groups at the 2- and 3-positions. It plays role in the formation of advanced glycation end-products (AGEs), a deleterious accompaniment to ageing.. aldose : Aldehydic parent sugars (polyhydroxy aldehydes H[CH(OH)]nC(=O)H, n >= 2) and their intramolecular hemiacetals.		1.9910aldotriosefundamental metabolite
gallopamil
Gallopamil: Coronary vasodilator that is an analog of iproveratril (VERAPAMIL) with one more methoxy group on the benzene ring.		1.9910benzenes;
organic amino compound
aniracetam
[no description available]		1.9910N-acylpyrrolidine;
pyrrolidin-2-ones
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		1.9910aromatic ether;
nitrile;
polyether;
tertiary amino compound
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		1.9910clonidine;
imidazoline
cyclothiazide
cyclothiazide: inhibits the desensitization of AMPA-type receptors; structure. cyclothiazide : 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted at positions 3, 5 and 6 by a 2-norbornen-5-yl group, chlorine, and a sulfonamide group, respectively. A thiazide diuretic, it has been used in the management of hypertension and oedema.		1.9910benzothiadiazineantihypertensive agent;
diuretic
diazoxide
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.		8.78110benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
berotek
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.		210resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		1.9910monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		1.9910benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
pinacidil
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)		2.9140pyridines
potassium chloride
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.		1.9810inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
tetraethylammonium
Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)		1.9910quaternary ammonium ion
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		1.9910N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
galactose
galactopyranose : The pyranose form of galactose.		1.9910D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
fura-2
Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.		1.9810
cromakalim
Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352)		1.9910
rubidium
Rubidium: An element that is an alkali metal. It has an atomic symbol Rb, atomic number 37, and atomic weight 85.47. It is used as a chemical reagent and in the manufacture of photoelectric cells.		1.9910alkali metal atom
7-chloro-3-isopropylamino-4h-1,2,4-benzothiadiazine 1,1-dioxide
7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide: activates ATP-sensitive potassium channels; structure in first source		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.9240
Compensatory Hyperinsulinemia
A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.		01.9910
Fasting Hypoglycemia
HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.		01.9910
Hyperinsulinism
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.		01.9910
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.		01.9910